Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioLineRx Ltd (BLRX) Fair Value & Analysis

Healthcare · Il · Market cap 41.8M ILA

Price0.0160 ILA
Fair Value0.0300 ILA
Upside+87.5%
Quality80/100
Evidence: Low Range 0.0200 ILA – 0.0400 ILA

Fair value as of: Jun 24, 2026

Analysis

BioLineRx Ltd (BLRX) currently trades at 0.0160 ILA, while our model-based Fair Value estimate is 0.0300 ILA — implying the stock looks roughly 87.5% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is BioLineRx Ltd (BLRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 0.0300 ILA versus a price of 0.0160 ILA — about +88% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BLRX?
Our 21-model fair value for BioLineRx Ltd is 0.0300 ILA (as of Jun 24, 2026), built from audited fundamentals. The current price is 0.0160 ILA.
What is the quality score of BLRX?
BioLineRx Ltd has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.